Grace Cherry
University of California, Los Angeles · 17 works · 15,431 citations · h-index 11
Top works
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
- Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
- Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations
- Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
- Diverse cutaneous adverse eruptions caused by anti-programmed cell death-1 (PD-1) and anti-programmed cell death ligand-1 (PD-L1) immunotherapies: clinical features and management
- Neoantigen-targeted CD8+ T cell responses with PD-1 blockade therapy
- Endocrinopathies with use of cancer immunotherapies
- Innate resistance of PD-1 blockade through loss of function mutations in JAK resulting in inability to express PD-L1 upon interferon exposure
- Acute Interstitial Nephritis and PR3-ANCA Following Reintroduction of Pembrolizumab: A Case Report
- Immune Checkpoint Inhibitor-Related Adrenal Insufficiency
- Acute kidney injury in patients receiving pembrolizumab combination therapy versus pembrolizumab monotherapy for advanced lung cancer
- 123 Landscape analysis of the neoepitope-specific T cell responses in patients with and without clinical benefit from immune checkpoint blockade therapy
- Data from Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations
- Data from Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations
- Supplementary Figures 1 - 16, Table 1, Database 1 from Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations